Ekta Khattar
Erica Salvati- 1Sunandan Divatia School of Science, SVKM’s NMIMS (Deemed to be) University, Mumbai, India
- 2Institute of Molecular Biology and Pathology, National Research Council, Rome, Italy
Editorial on the Research Topic
Novel insights connecting telomere biology to cancer development and progression
Introduction
Telomere length maintenance represents a unique connection between replicative senescence and carcinogenesis, functioning like a double-edged sword. Telomere shortening suppresses cancer development in normal cells, limiting their replicative potential. Contrarily, in precancerous lesions, telomeric dysfunction, arising from telomere shortening, may promote genomic instability, fueling cancer development. Therefore, investigating proteins and genes involved in telomere homeostasis offers great opportunities for developing targeted therapies and for identifying novel markers of cancer initiation and progression.
More than 80% of cancers attain replicative immortality predominantly through activation of telomerase, which mostly occurs through TERT re-expression during cancer initiation and development (1, 2). Telomerase enzyme consists of a catalytic subunit called telomerase reverse transcriptase (TERT), which adds nucleotides to the extending 3’ telomeric DNA strand by using an RNA template called telomerase RNA component (TERC or TR) (3). The presence of functionally active telomerase confers cells with the ability to undergo infinite cell division without losing essential genetic elements. 10 to 15% of cancer cells elongate telomeres using alternative lengthening of telomeres (ALT) using telomeric recombination (4).
Telomere metabolism involves specialized functional complexes located at telomeres like shelterin and CST complexes. Shelterin is a six-member complex with a high affinity for telomeric DNA. It comprises TRF1, TRF2, POT1, TPP1, TIN2 and RAP1 proteins. Shelterin complex is mainly involved in the inhibition of inappropriate activation of DDR at telomeres, which could promote telomere recombination and genome instability (5). CST is a trimeric complex consisting of CTC, Stn1, and Ten1 in humans (6). CST complex associates with single-stranded telomeric overhang and prevents telomerase association with telomeres while promoting the association of DNA polymerase α/primase to promote telomeric C-strand fill-in reaction (7–9). This coordination of G and C-strand synthesis occurs in the late S-early G2 phase when telomerase extension of telomeric G-strand is completed (10, 11).
This editorial summarizes the recent achievements in the field of telomere biology and cancer with a collection of two case reports, original research articles and brief research reports, and a review article published over a few months in the Frontiers Research Topic Novel insights connecting telomere biology to cancer development and progression.
In a case report, He et al. reported a mutation in the CST component gene, CTC1, which was associated with a benign form of cancer, namely liver hemangioma. Hemangiomas are generally asymptomatic but can be complicated if they become giant and diffuse, where they tend to be extrahepatic as well. Authors performed whole exome sequencing and identified heterozygous variants of the CTC1 gene: a splicing site mutation, c.435 + 9A>C, and a missense mutation, c.3074C>T (p.Ala1025Val), which may be involved in vascular disease pathology.
In the second case report of this Research Topic, Nisar et al. report a pathological mutation in the RTEL1 gene (regulator of telomere elongation helicase 1) in a dyskeratosis congenital (DKC) patient. Authors performed targeted sequencing of nine genes involved in DKC pathogenesis, shortlisted based on literature. They report a novel homozygous RTEL1 gene variant c.2060C>T (p.Ala687Val) in the patient. Functional assay of the mutant protein is not reported.
The onset of telomere lengthening mechanisms is an early event in cancer development and the comprehension of this process is a major goal for cancer research. In an original research article, Udroiu et al. investigated the effects of the inhibition of ATRX and p53 proteins in aged primary fibroblasts on ALT activity. Udroiu et al. reported the activation of the ALT pathway upon p53 silencing in aged fibroblasts, associated with an increased telomeric recombination due to a de-repression of the homologous recombination (HR) pathway. Since ALT cancers are characterized by p53 and ATRX mutations, this paper highlights a potential mechanism of induction of ALT activity occurring in aged human tissues during oncogenesis.
A novel regulatory mechanism, acting at ALT-positive telomeres, is reported by Tang et al. In this research article, Tang and coauthors present experimental evidence that the shelterin protein TRF2 recruits MRE11 and UBR5 to suppress the RNF168-53BP1 dependent cNHEJ mediated telomeric fusion at ALT telomeres. Of note, loss of this regulation would be tumor suppressive. This finding could pave the way for the generation of small molecules or peptides that could specifically disrupt this mechanism triggering telomeric shortening and cancer cell death.
Telomere length is a hallmark for cancer cells, and has been frequently correlated with cancer aggressiveness, response to treatment or disease recurrence. Two research articles in this Research Topic addresses this important point.
Li et al. investigated the correlation between telomere length and prognosis of breast cancer with varying expression of estrogen receptor (ER) using the Mendelian randomization approach. The authors report that longer telomeres could predict a poor prognosis of ER-negative breast cancer, while no significant correlation was observed between ER-positive breast cancer and telomere length. This substantially confirms the telomere lengthening as a biomarker for cancer prognosis and as a target for cancer treatment.
An important role of telomere length in prediction of the risk of post-transplant malignancy (PTM) is reported by Petrara et al. Telomere erosion in activated and exhausted T and B cells at baseline determined a higher risk of PTM in liver-transplanted patients for hepatocellular cancer development compared to that receiving transplant due to other reasons. This suggests that telomere attrition, determined by immune activation and exhaustion, may be useful to predict the risk of PTM occurrence. In addition, this finding suggests that T-cell senescence can represent an additional risk factor for tumor onset in LT-HCC.
Targeting telomere lengthening and telomeric components using direct inhibitors and their combination with other effective anti-tumor drugs represents a promising therapeutic opportunity to selectively hit cancer cells.
In a research article, Chebly et al. investigated the effect of epidrugs on the proliferation of Sézary cells using in vitro studies. Sézary syndrome (SS) is an aggressive leukemic variant of cutaneous T-cell lymphomas in which the TERT gene is re-expressed. The group of Chebly et al. report that 5-azacytidine, romidepsin, and vorinostat epidrugs combination could downregulate TERT expression and reduce tumorigenic potential of SS cells.
Finally, in a review article, Banikazemi et al. reviewed in detail the most recent achievements obtained with the employment of coumarins derivatives for the treatment of gastrointestinal cancer (GC). Banikazemi et al. analysed in detail the mechanistic action of the natural product coumarin for its anti-tumor activity. As reported, coumarins exhibit a variety of functions, including hormone antagonism, DNA alkylation, angiogenesis inhibition, telomerase, topoisomerase and carbonic anhydrase inhibition, apoptosis inhibition, antimitotic effect etc, and still represent a valid therapeutic opportunity for the treatment of GC.
Overall, the Research Topic strengthen the importance of telomere maintenance in the development and progression of cancer and its therapeutic potential as target and as biomarker.
Nevertheless, many of the studies are specific to tumor types and disease conditions and require further investigation with strong experimentation and validation. Further studies in the field will help to develop a better understanding of the role of telomere-associated proteins and genes in the initiation, development, and treatment of various cancer types.
Author contributions
EK: Writing – review & editing, Writing – original draft. ES: Writing – review & editing, Writing – original draft.
Funding
The author(s) declare financial support was received for the research, authorship, and/or publication of this article. EK is supported by grants from DST SERB ECRA (ECR/2018/002117), Govt. of India and DBT (No. BT/RLF/Re-entry/06/2015), Govt. of India. ES is supported by CNR project FOE-2021 DBA.AD005.225.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
1. Fernandes SG, Dsouza R, Pandya G, Kirtonia A, Tergaonkar V, Lee SY, et al. Role of telomeres and telomeric proteins in human Malignancies and their therapeutic potential. Cancers (Basel). (2020) 12:1901. doi: 10.3390/cancers12071901
2. Greider CW, Blackburn EH. Identification of a specific telomere terminal transferase activity in Tetrahymena extracts. Cell. (1985) 43:405–13. doi: 10.1016/0092-8674(85)90170-9
3. Greider CW, Blackburn EH. The telomere terminal transferase of Tetrahymena is a ribonucleoprotein enzyme with two kinds of primer specificity. Cell. (1987) 51:887–98. doi: 10.1016/0092-8674(87)90576-9
4. Bryan TM, Englezou A, Dalla-Pozza L, Dunham MA, Reddel RR. Evidence for an alternative mechanism for maintaining telomere length in human tumors and tumor-derived cell lines. Nat Med. (1997) 3:1271–4. doi: 10.1038/nm1197-1271
5. Denchi EL, de Lange T. Protection of telomeres through independent control of ATM and ATR by TRF2 and POT1. Nature. (2007) 448:1068–71. doi: 10.1038/nature06065
6. Bryan C, Rice C, Harkisheimer M, Schultz DC, Skordalakes E. Structure of the human telomeric Stn1-Ten1 capping complex. PloS One. (2013) 8:e66756. doi: 10.1371/journal.pone.0066756
7. Chen LY, Redon S, Lingner J. The human CST complex is a terminator of telomerase activity. Nature. (2012) 488:540–4. doi: 10.1038/nature11269
8. Feng X, Hsu SJ, Kasbek C, Chaiken M, Price CM. CTC1-mediated C-strand fill-in is an essential step in telomere length maintenance. Nucleic Acids Res. (2017) 45:4281–93. doi: 10.1093/nar/gkx125
9. Feng X, Hsu SJ, Bhattacharjee A, Wang Y, Diao J, Price CM. CTC1-STN1 terminates telomerase while STN1-TEN1 enables C-strand synthesis during telomere replication in colon cancer cells. Nat Commun. (2018) 9:2827. doi: 10.1038/s41467-018-05154-z
10. Wang F, Stewart JA, Kasbek C, Zhao Y, Wright WE, Price CM. Human CST has independent functions during telomere duplex replication and C-strand fill-in. Cell Rep. (2012) 2:1096–103. doi: 10.1016/j.celrep.2012.10.007
Keywords: telomere, telomere length, telomerase, cancer, shelterin complex, alternative lengthening of telomeres
Citation: Khattar E and Salvati E (2024) Editorial: Novel insights connecting telomere biology to cancer development and progression. Front. Oncol. 14:1405618. doi: 10.3389/fonc.2024.1405618
Received: 23 March 2024; Accepted: 02 April 2024;
Published: 16 April 2024.
Edited and Reviewed by:
Tao Liu, University of New South Wales, AustraliaCopyright © 2024 Khattar and Salvati. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Ekta Khattar, ekta.khattar@nmims.edu; Erica Salvati, erica.salvati@cnr.it